Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is a promising clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases, with a strong emphasis on the function of regulatory T cells. The recent publication of a peer-reviewed study showcasing the elevated biomarkers for ALS strengthens the company's rationale and framework for its approach, while also differentiating it from other late-stage ALS therapies. Additionally, the company's FY2025 financial results demonstrate a healthy balance sheet and promising clinical updates, positioning it for potential success in its lead asset, COYA 302.

Bears say

Coya Therapeutics is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases, but has yet to provide registrational evidence to support its pipeline. While their most recent publication in Brain Communications reinforces the biologic rationale for one of their programs, it does not have a significant impact on financial estimates. However, the release does provide external validation to their platform and helps to de-risk their scientific foundation for future development.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.